Cervical cancer is one of the few cancers we know how to prevent. It should be a public health success story. And yet it still kills thousands of women in the United States every year. That reality is hard to ignore.

It is even harder to ignore in Pennsylvania, where clinics that provide cervical cancer screening to low-income and uninsured women are under threat.

No progress

Cervical cancer is largely preventable through effective HPV vaccines, reliable screening, and early detection. Few cancers offer such a clear and achievable pathway to eradication. And yet, the United States has made almost no progress.

More than two decades ago, the American Cancer Society warned that many cervical cancer deaths were preventable with improved early detection — a problem policymakers recognized as driven by inadequate screening. At the time, about 13,000 women were diagnosed annually and roughly 4,100 died.

Advertise with us

Nearly a quarter century later, those numbers remain essentially unchanged. In 2026, an estimated 13,490 women will be diagnosed, and about 4,200 will die.

It is possible to do better. Australia is on track to eliminate cervical cancer, a milestone largely driven by high vaccination rates and coordinated screening programs. The World Health Organization has outlined a clear and achievable strategy to do the same globally: vaccinate 90 percent of girls against HPV by age 15, screen 70 percent of women by ages 35 and 45, and ensure 90 percent of those with cervical disease receive treatment.

A 2021 report showed that scaling up screening coverage alone could accelerate elimination to as early as 2028 — it was well within reach if the political will had existed to try.

The problem

The problem is not a lack of direction. The problem is how the U.S. health system works. Preventive care here is fragmented and often dependent on insurance status, geography, and political decisions. Instead of treating prevention as a public health obligation, the system treats it as an individual responsibility.

At the same time, misinformation and politicization have fueled hesitancy around the HPV vaccine, undermining one of the most effective cancer-prevention tools available. All this leads to predictable results. Roughly one in four U.S. women is not up to date on cervical cancer screening, and about half of cases occur among women who were never or rarely screened.

Advertise with us

Pennsylvania expanded Medicaid under the Affordable Care Act, a decision that has been associated with higher screening rates and improved access to care – evidence that access is the central issue. But coverage alone is not enough if the providers delivering that care in the state are disappearing.

Funding for Title X family planning providers, a key source of preventive services for low-income patients, has been repeatedly targeted at the federal level. Adagio Health, which administers the state’s Breast and Cervical Cancer Early Detection Program across 62 counties, has warned that funding cuts have placed approximately 50 clinical sites at risk.

These clinics provide Pap smears, HPV testing, and follow-up care to women who often have nowhere else to turn. When those sites close or reduce services, access disappears.

The burden of that loss is not evenly distributed. Uninsured women and low income women face the greatest barriers to screening. The disparities are also racial. Hispanic and Black women are more likely to be diagnosed with cervical cancer, and Black women have the highest mortality rates — driven by delayed diagnosis, unequal access to care, and longstanding systemic inequities.

There are signs of progress. State programs like Pennsylvania's own early detection program have worked to connect thousands of women to lifesaving care over the past decade. The Food and Drug Administration’s approval of at-home HPV self-collection testing, now entering broader clinical use, could expand screening to women who face logistical or geographic barriers to in-person care.

Advertise with us

The solutions

The solutions are not complicated. Protecting and expanding Medicaid coverage remains essential to reducing the number of uninsured women.

Sustained state and federal investment in community-based clinics — including Title X providers — is critical to maintaining access to screening and follow-up care. Pennsylvania has the opportunity to follow states like California and Illinois in using state funds to stabilize its safety-net providers when federal support falls short.

Restoring credible leadership on vaccine safety would further strengthen uptake of one of the most effective cancer-prevention tools available. And scaling at-home screening options could help reach women who have long been left out of traditional care models.

Cervical cancer is preventable. Its persistence is a policy choice. Until the United States treats prevention as a public health responsibility rather than an individual burden, cervical cancer will remain a disease that disproportionately harms those with the least access to care.

The tools to eliminate it already exist. What is missing is the political will to use them.

Briana Torres, an attorney, is the Maeve McKean Women’s Law and Public Policy Fellow at Georgetown University’s O’Neill Institute for National and Global Health Law a fellow with the National Health Law Program.